Role of pharmaceutical care in dual anti-infective treatment of refractory mycoplasma pneumonia in children

YAN Xiao-ling; HE Han-jun; ZHANG Song

doi:10.3969/j.issn.1672-8157.2023.06.027

Abstract：Objective:To investigate the efficacy of pharmaceutical care in dual anti-infective treatmentcombined with Refractory mycoplasma pneumonia(RMPP)in the treatment of refractory mycoplasma pneumonia(RMPP)and its impact on the recovery process and prognosis.Methods:A total of 108 caseschildren patients of with RMPP children inadmitted to our hospital from May 2021 to April 2023 were retrospectively selected as the study objects and divided into two groups according to different treatment methods.The 54 casespatients in the control group received conventional dual anti-infection therapy,and the other 54 cases in the observation group received pharmaceutical care with the participation of clinical pharmacists.The therapeutic effect,rehabilitation process,cost-effectiveness analysis,incidence of adverse reactions,inflammatory factors before and after treatment,as well aspulmonary function indexes were compared between the two 2 groups.Results:The total effective rate of observation group was 94.44%(51/54),which was higher than that of the controlgroup 74.07%(40/54)(P<0.05).The disappearance time of cough,fever,lung rura,lung X-ray shadow and hospital stay in the observation group were(6.67±1.37)d,(4.25±1.12)d,(7.22±1.55)d,(10.53±2.41)d and(14.87±2.57)d,respectively,which were all shorter than those in the control group((8.92±1.60)d,(5.83±1.34)d,(9.80±1.81)d,(13.76±3.06)d,(16.38±3.11)d)(all P<0.05).After treatment for 7 days and 14 days,the serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP),IL-8 and transforming growth factor-β1(TGF-β1)in the observation group were all lower than those in the control group(all P<0.05).After treatment for 7 days and 14 days,the ratio of forced expiratory volume in the first second to forced vital capacity(FEV1/FVC),the maximum mid-expiratory flow rate(MMF),the instantaneous flow rate(PEF25)and the maximum expiratory flow rate(PEF)at forced expiratory 25%in the observation group were all higher than those in the control group(all P<0.05).The cost-effectiveness ratio of observation components the observation group(21.74±6.59)was lower than that of the control group(42.21±10.24)(P<0.05).One treatment unit cost 21.74 yuan in the observation group and 42.21 yuan in the control group.The control group spent 5 273.34 yuan more than the observation group.The incidence of adverse reactions in the observation group was lower than that in the control group(5.56%,18.52%)(P<0.05).Conclusion:Adding pharmaceutical care on the basis of dual anti-infective therapy can further reduce the level of serum inflammatory factors in RMPP patients,improve lung function,and promote disease rehabilitation,with accurate effects,higher safety,and more cost-effectiveness advantages.